Microbiome-Modulating Nanoplatforms for Breast Cancer Therapy

Breast tumors comprise interacting malignant, stromal, immune, and microbial compartments, while gut microbial communities can influence systemic immunity, drug metabolism, and therapeutic response. Emerging evidence therefore positions the microbiome as a potential modifier of breast cancer progression and treatment efficacy rather than merely a passive correlate of disease. Nanotechnology offers experimental approaches to couple tumor-directed drug delivery with selective manipulation of intratumoral or intestinal microbiota. Liposomal, lipid-based, inorganic, biomimetic, and biohybrid platforms have been used to reduce tumor-associated bacteria, alter microbial communities or metabolites, and modify antitumor immune responses. Several platforms further combine microbiota modulation with chemotherapy, immunotherapy, ferroptosis induction, or externally activated treatment. However, improved tumor control cannot necessarily be attributed to microbial modulation because many of these systems independently alter drug exposure, tumor-cell viability, oxidative stress, or immune activity. Evidence for microbiota dependence remains largely preclinical and is frequently derived from experimentally colonized or bacteria-enriched tumor models. Low microbial biomass, contamination risk, interpatient microbiome heterogeneity, methodological variability, ecological consequences of microbial depletion, manufacturing complexity, and the absence of clinical validation further constrain translation. This review critically evaluates microbiome-modulating nanoplatforms in breast cancer, distinguishes microbiota-associated from microbiota-dependent therapeutic effects, and defines the mechanistic, analytical, and clinical evidence needed to establish microbiome targeting as a viable component of precision breast cancer therapy

Authors

Publication Details

Journal
Cancer Biome and Targeted Therapy
Published
2026-11-14
DOI
https://doi.org/10.66505/cbtt.v1i4.59
Primary Topic
Bacterial Cancer Therapy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Microbiome-Modulating Nanoplatforms for Breast Cancer Therapy

Ajay Sharma, Khang Wen Goh, Amirhossein Sahebkar, Prashant Kesharwani et al.
Cancer Biome and Targeted Therapy
Bacterial Cancer Therapy
article

Microbiome-Modulating Nanoplatforms for Breast Cancer Therapy

Ajay Sharma, Khang Wen Goh, Amirhossein Sahebkar, Prashant Kesharwani, Muskan Leharwani, Akanksha Pawar, Garima Gupta
article en

Abstract

Breast tumors comprise interacting malignant, stromal, immune, and microbial compartments, while gut microbial communities can influence systemic immunity, drug metabolism, and therapeutic response. Emerging evidence therefore positions the microbiome as a potential modifier of breast cancer progression and treatment efficacy rather than merely a passive correlate of disease. Nanotechnology offers experimental approaches to couple tumor-directed drug delivery with selective manipulation of intratumoral or intestinal microbiota. Liposomal, lipid-based, inorganic, biomimetic, and biohybrid platforms have been used to reduce tumor-associated bacteria, alter microbial communities or metabolites, and modify antitumor immune responses. Several platforms further combine microbiota modulation with chemotherapy, immunotherapy, ferroptosis induction, or externally activated treatment. However, improved tumor control cannot necessarily be attributed to microbial modulation because many of these systems independently alter drug exposure, tumor-cell viability, oxidative stress, or immune activity. Evidence for microbiota dependence remains largely preclinical and is frequently derived from experimentally colonized or bacteria-enriched tumor models. Low microbial biomass, contamination risk, interpatient microbiome heterogeneity, methodological variability, ecological consequences of microbial depletion, manufacturing complexity, and the absence of clinical validation further constrain translation. This review critically evaluates microbiome-modulating nanoplatforms in breast cancer, distinguishes microbiota-associated from microbiota-dependent therapeutic effects, and defines the mechanistic, analytical, and clinical evidence needed to establish microbiome targeting as a viable component of precision breast cancer therapy

Cancer Biome and Targeted Therapy
Bacterial Cancer Therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon